Corvus Pharmaceuticals
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell CRVS and other ETFs, options, and stocks.About CRVS
Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor.
CRVS Key Statistics
Stock Snapshot
The current Corvus Pharmaceuticals(CRVS) stock price is $14.87, with a market capitalization of 1.28B. The stock trades at a price-to-earnings (P/E) ratio of -28.64.
On 2026-03-15, Corvus Pharmaceuticals(CRVS) stock moved within a range of $14.59 to $16.44. With shares now at $14.87, the stock is trading +1.9% above its intraday low and -9.5% below the session's peak.
Trading activity shows a volume of 1.22M, compared to an average daily volume of 1.11M.
The stock's 52-week range extends from a low of $2.54 to a high of $26.95.
The stock's 52-week range extends from a low of $2.54 to a high of $26.95.
CRVS News
Advertisement Corvus Pharmaceuticals stock moves after recent performance swings Corvus Pharmaceuticals (CRVS) has been drawing fresh attention as its share p...
Corvus Pharmaceuticals ( (CRVS) ) just unveiled an update. On March 13, 2026, Corvus Pharmaceuticals amended and restated its open market sale agreement with J...
Oppenheimer raised the firm’s price target on Corvus Pharmaceuticals (CRVS) to $33 from $32 and keeps an Outperform rating on the shares after the company repor...
Analyst ratings
100%
of 7 ratingsMore CRVS News
Image source: The Motley Fool. Thursday, March 12, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Chief Financial Officer — Leiv Lea President and Chief Executive Offi...
Earnings Call Insights Corvus outlines cash runway into Q2 2028 and targets mid-2027 Phase II readout for soquelitinib in atopic dermatitis Mar. 12, 2026 9:32 P...
“We believe the recent cohort 4 data from our Phase 1 atopic dermatitis trial demonstrate that soquelitinib has the potential to be an important new medicine fo...
Corvus Pharmaceuticals Inc. (CRVS) announced an update on their ongoing clinical study. The Phase 1 study titled “A Phase 1, Randomized, Blinded, Placebo-contr...
If you are wondering whether Corvus Pharmaceuticals' recent share price puts it at a bargain or a stretched level, you are not alone. This article is here to un...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.